1. Home
  2. VWAV vs MOLN Comparison

VWAV vs MOLN Comparison

Compare VWAV & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VWAV

VisionWave Holdings Inc.

N/A

Current Price

$10.82

Market Cap

152.5M

Sector

Technology

ML Signal

N/A

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.18

Market Cap

151.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VWAV
MOLN
Founded
2024
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
152.5M
151.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
VWAV
MOLN
Price
$10.82
$4.18
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
487.3K
5.7K
Earning Date
02-26-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$999.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.06
$3.36
52 Week High
$18.41
$5.41

Technical Indicators

Market Signals
Indicator
VWAV
MOLN
Relative Strength Index (RSI) 47.22 49.36
Support Level $9.80 $3.97
Resistance Level $11.00 $4.27
Average True Range (ATR) 1.45 0.16
MACD -0.28 -0.01
Stochastic Oscillator 13.33 38.95

Price Performance

Historical Comparison
VWAV
MOLN

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is engaged in revolutionizing defense capabilities by integrating artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its innovations range from high-resolution radars and vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications globally.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: